324 related articles for article (PubMed ID: 25865025)
1. Ultrasound-enhanced bevacizumab release from echogenic liposomes for inhibition of atheroma progression.
Klegerman ME; Naji AK; Haworth KJ; Zou Y; Golunski E; Peng T; Britton GL; Huang SL; Holland CK; McPherson DD
J Liposome Res; 2016; 26(1):47-56. PubMed ID: 25865025
[TBL] [Abstract][Full Text] [Related]
2. Delivery of bevacizumab to atheromatous porcine carotid tissue using echogenic liposomes.
Sutton JT; Haworth KJ; Shanmukhappa SK; Moody MR; Klegerman ME; Griffin JK; Patton DM; McPherson DD; Holland CK
Drug Deliv; 2016 Nov; 23(9):3594-3605. PubMed ID: 27689451
[TBL] [Abstract][Full Text] [Related]
3. Ultrasound-triggered release of recombinant tissue-type plasminogen activator from echogenic liposomes.
Smith DA; Vaidya SS; Kopechek JA; Huang SL; Klegerman ME; McPherson DD; Holland CK
Ultrasound Med Biol; 2010 Jan; 36(1):145-57. PubMed ID: 19900755
[TBL] [Abstract][Full Text] [Related]
4. Multivesicular liposomes for sustained release of bevacizumab in treating laser-induced choroidal neovascularization.
Mu H; Wang Y; Chu Y; Jiang Y; Hua H; Chu L; Wang K; Wang A; Liu W; Li Y; Fu F; Sun K
Drug Deliv; 2018 Nov; 25(1):1372-1383. PubMed ID: 29869520
[TBL] [Abstract][Full Text] [Related]
5. Comparative effects of bevacizumab, ranibizumab and pegaptanib at intravitreal dose range on endothelial cells.
Carneiro A; Falcão M; Pirraco A; Milheiro-Oliveira P; Falcão-Reis F; Soares R
Exp Eye Res; 2009 Mar; 88(3):522-7. PubMed ID: 19135441
[TBL] [Abstract][Full Text] [Related]
6. Nitric Oxide-Enhanced Molecular Imaging of Atheroma using Vascular Cellular Adhesion Molecule 1-Targeted Echogenic Immunoliposomes.
Kim H; Kee PH; Rim Y; Moody MR; Klegerman ME; Vela D; Huang SL; McPherson DD; Laing ST
Ultrasound Med Biol; 2015 Jun; 41(6):1701-10. PubMed ID: 25819469
[TBL] [Abstract][Full Text] [Related]
7. Arming embolic beads with anti-VEGF antibodies and controlling their release using LbL technology.
Sakr OS; Berndt S; Carpentier G; Cuendet M; Jordan O; Borchard G
J Control Release; 2016 Feb; 224():199-207. PubMed ID: 26780173
[TBL] [Abstract][Full Text] [Related]
8. In vivo volumetric intravascular ultrasound visualization of early/inflammatory arterial atheroma using targeted echogenic immunoliposomes.
Kim H; Moody MR; Laing ST; Kee PH; Huang SL; Klegerman ME; McPherson DD
Invest Radiol; 2010 Oct; 45(10):685-91. PubMed ID: 20733507
[TBL] [Abstract][Full Text] [Related]
9. Liposomal
Blocker SJ; Douglas KA; Polin LA; Lee H; Hendriks BS; Lalo E; Chen W; Shields AF
Theranostics; 2017; 7(17):4229-4239. PubMed ID: 29158822
[TBL] [Abstract][Full Text] [Related]
10. Ultrasound-facilitated thrombolysis using tissue-plasminogen activator-loaded echogenic liposomes.
Tiukinhoy-Laing SD; Huang S; Klegerman M; Holland CK; McPherson DD
Thromb Res; 2007; 119(6):777-84. PubMed ID: 16887172
[TBL] [Abstract][Full Text] [Related]
11. Anti-vascular endothelial growth factor antibody attenuates inflammation and decreases mortality in an experimental model of severe sepsis.
Jeong SJ; Han SH; Kim CO; Choi JY; Kim JM
Crit Care; 2013 May; 17(3):R97. PubMed ID: 23710641
[TBL] [Abstract][Full Text] [Related]
12. Inhibiting angiogenesis with human single-chain variable fragment antibody targeting VEGF.
Hosseini H; Rajabibazl M; Ebrahimizadeh W; Dehbidi GR
Microvasc Res; 2015 Jan; 97():13-8. PubMed ID: 25250517
[TBL] [Abstract][Full Text] [Related]
13. [Efficacy of internalized RGD-modified echogenic liposomes in diagnosis and treatment in a mouse model of rheumatoid arthritis].
Gan Z; Wu H; Wu HH; Zhou MJ; Yan F; Liu HM
Nan Fang Yi Ke Da Xue Xue Bao; 2017 Oct; 37(10):1283-1289. PubMed ID: 29070455
[TBL] [Abstract][Full Text] [Related]
14. Liposomal modular complexes for simultaneous targeted delivery of bioactive gases and therapeutics.
Klegerman ME; Wassler M; Huang SL; Zou Y; Kim H; Shelat HS; Holland CK; Geng YJ; McPherson DD
J Control Release; 2010 Mar; 142(3):326-31. PubMed ID: 19903503
[TBL] [Abstract][Full Text] [Related]
15. Nitric oxide improves molecular imaging of inflammatory atheroma using targeted echogenic immunoliposomes.
Kim H; Kee PH; Rim Y; Moody MR; Klegerman ME; Vela D; Huang SL; McPherson DD; Laing ST
Atherosclerosis; 2013 Dec; 231(2):252-60. PubMed ID: 24267236
[TBL] [Abstract][Full Text] [Related]
16. Ultrasound-mediated release of hydrophilic and lipophilic agents from echogenic liposomes.
Kopechek JA; Abruzzo TM; Wang B; Chrzanowski SM; Smith DA; Kee PH; Huang S; Collier JH; McPherson DD; Holland CK
J Ultrasound Med; 2008 Nov; 27(11):1597-606. PubMed ID: 18946099
[TBL] [Abstract][Full Text] [Related]
17. Synthesis, acoustic stability, and pharmacologic activities of papaverine-loaded echogenic liposomes for ultrasound controlled drug delivery.
Kee PH; Abruzzo TA; Smith DA; Kopechek JA; Wang B; Huang SL; MacDonald RC; Holland CK; McPherson DD
J Liposome Res; 2008; 18(4):263-77. PubMed ID: 18720194
[TBL] [Abstract][Full Text] [Related]
18. The efficacy of anti-VEGF antibody-modified liposomes loaded with paeonol in the prevention and treatment of hypertrophic scars.
Shi J; Wu Y; Guo S; Zhang H; Chen G; Xu X
Drug Dev Ind Pharm; 2019 Mar; 45(3):439-455. PubMed ID: 30512972
[TBL] [Abstract][Full Text] [Related]
19. Modulation of bevacizumab-induced toxicity for cultured human corneal fibroblasts.
Kim EK; Kang SW; Kim JY; Min K; Kim TI
Invest Ophthalmol Vis Sci; 2013 Jun; 54(6):3922-31. PubMed ID: 23640039
[TBL] [Abstract][Full Text] [Related]
20. Analytical similarity assessment of MYL-1402O to reference Bevacizumab.
Goyal P; Vats B; Subbarao M; Honnappa CG; Kabadi P; Rohil S; Bera A; Mehta GR; Pai H; Adhikari L; Tagore R; Sharma S; Venkatachala R; Nair P; Annegowda S; Sahu A; Trivedi S; Shastri N; Gokhale Y; Thomas R; Thakur A; Mohan D; Rao K U; Melarkode R; Ullanat R
Expert Opin Biol Ther; 2022 Feb; 22(2):271-298. PubMed ID: 34465264
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
